劲方医药(02595.HK) 公布,GFH375单药治疗KRAS G12D突变型实体瘤研究的更新数据,登陆今年美国临床肿瘤学会(ASCO)年会的口头报告。报告展现GFH375单药治疗胆管癌(CCA)和结直肠癌(CRC)的初步疗效。当中,20例KRAS G12D突变型经治胆管癌患者完成至少一次治疗后肿瘤评估:所有剂量水平的总体客观缓解率(ORR)为40%、疾病控制率(DCR)为95%;其中600mg...
Source Link劲方医药(02595.HK) 公布,GFH375单药治疗KRAS G12D突变型实体瘤研究的更新数据,登陆今年美国临床肿瘤学会(ASCO)年会的口头报告。报告展现GFH375单药治疗胆管癌(CCA)和结直肠癌(CRC)的初步疗效。当中,20例KRAS G12D突变型经治胆管癌患者完成至少一次治疗后肿瘤评估:所有剂量水平的总体客观缓解率(ORR)为40%、疾病控制率(DCR)为95%;其中600mg...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.